(PRTG) – Globe Newswire
-
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
-
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
-
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
-
Portage Biotech Reports Business and Strategic Update
-
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
-
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
-
Portage Biotech Announces $6.0 Million Registered Direct Offering
-
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
-
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
-
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update
-
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
-
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
-
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American S
-
Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference
-
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference
-
Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022
-
Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer
-
Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
-
Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022
-
Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
-
Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
-
Portage Biotech Provides Research and Development Update
-
Portage Biotech to Present at Upcoming Investor Conferences
-
Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022
-
Portage Biotech Announces Leadership Updates
-
UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
-
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
-
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
-
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
-
Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Biohaven Pharmaceutical Holding Company Ltd. (NYSE - BHVN), Tiga Acquisition Corp. (NYSE - TINV), Lakeshore
-
BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BHVN and Encourages Investors to Contact the Firm
-
BHVN Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Biohaven Pharmaceutical to Pfizer
-
Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
-
Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting
-
Portage Biotech Provides Update on Clinical-Stage and Development Programs
-
Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting
-
Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year
-
Portage Biotech Announces New Appointments to its Management Team and Board of Directors
-
Portage Biotech Announces Participation in January 2022 Investor Conferences
-
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
-
Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference
-
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease
-
Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics’ INT230-6 (PORT-1) at November Scientific Conferences
-
Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment
-
Portage Biotech Announces Participation in September 2021 Investor Conferences
-
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
-
Portage Biotech Issues Letter to Shareholders
-
Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)
Back to PRTG Stock Lookup
